Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...

Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to outperform in 2025. Here’s what you need to know.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

Based in San Diego, California, ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and ...

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Read more. ResMed CPAP masks subject to Class I recall over magnetic interference issue Six reported injuries related to magnets on the headgear of CPAP machines by ResMed Ltd. have resulted in a ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.